BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34330303)

  • 21. Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.
    Viol F; Sipos B; Fahl M; Clauditz TS; Amin T; Kriegs M; Nieser M; Izbicki JR; Huber S; Lohse AW; Schrader J
    Cell Oncol (Dordr); 2022 Dec; 45(6):1401-1419. PubMed ID: 36269546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors.
    Di Mauro A; Scognamiglio G; Aquino G; Cerrone M; Liguori G; Clemente O; Di Bonito M; Cantile M; Botti G; Tafuto S; Tatangelo F
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
    JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany.
    Scherübl H; Streller B; Stabenow R; Herbst H; Höpfner M; Schwertner C; Steinberg J; Eick J; Ring W; Tiwari K; Zappe SM
    World J Gastroenterol; 2013 Dec; 19(47):9012-9. PubMed ID: 24379626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
    Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035
    [No Abstract]   [Full Text] [Related]  

  • 27. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nutritional Complications and the Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Laing E; Kiss N; Michael M; Krishnasamy M
    Neuroendocrinology; 2020; 110(5):430-442. PubMed ID: 31550712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evening chronotype is associated with metabolic disorders and body composition in middle-aged adults.
    Yu JH; Yun CH; Ahn JH; Suh S; Cho HJ; Lee SK; Yoo HJ; Seo JA; Kim SG; Choi KM; Baik SH; Choi DS; Shin C; Kim NH
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1494-502. PubMed ID: 25831477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors associated with gastroenteropancreatic neuroendocrine tumors in a cohort of 2.3 million Israeli adolescents.
    Katz LH; Levi Z; Twig G; Kark JD; Leiba A; Derazne E; Liphshiz I; Keinan-Boker L; Eisenstein S; Afek A
    Int J Cancer; 2018 Oct; 143(8):1876-1883. PubMed ID: 29744856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.
    Shi M; Fan Z; Xu J; Yang J; Li Y; Gao C; Su P; Wang X; Zhan H
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188637. PubMed ID: 34678439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GEP-NET radiomics: a systematic review and radiomics quality score assessment.
    Staal FCR; Aalbersberg EA; van der Velden D; Wilthagen EA; Tesselaar MET; Beets-Tan RGH; Maas M
    Eur Radiol; 2022 Oct; 32(10):7278-7294. PubMed ID: 35882634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution.
    Guo LJ; Wang CH; Tang CW
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):284-8. PubMed ID: 27170574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor.
    Tamagno G; Sheahan K; Skehan SJ; Geoghegan JG; Fennelly D; Collins CD; Maguire D; Traynor O; Brophy DP; Cantwell C; Swan N; McGowan L; O'Toole D; O'Shea D
    Endocrine; 2013 Oct; 44(2):504-9. PubMed ID: 23471696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review.
    Watson C; Tallentire CW; Ramage JK; Srirajaskanthan R; Leeuwenkamp OR; Fountain D
    World J Gastroenterol; 2020 Jul; 26(25):3686-3711. PubMed ID: 32742136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
    Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
    Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
    Baeg K; Harris C; Naparst MS; Ahn E; Thapi S; Martin J; Rustgi S; Mhango G; Wisnivesky J; Kim MK
    BMC Cancer; 2021 Feb; 21(1):146. PubMed ID: 33563241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
    Strosberg JR
    Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.